JP2012506870A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506870A5
JP2012506870A5 JP2011533397A JP2011533397A JP2012506870A5 JP 2012506870 A5 JP2012506870 A5 JP 2012506870A5 JP 2011533397 A JP2011533397 A JP 2011533397A JP 2011533397 A JP2011533397 A JP 2011533397A JP 2012506870 A5 JP2012506870 A5 JP 2012506870A5
Authority
JP
Japan
Prior art keywords
use according
acyl
hydrogen
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533397A
Other languages
English (en)
Japanese (ja)
Other versions
JP5711135B2 (ja
JP2012506870A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/061976 external-priority patent/WO2010048599A1/en
Publication of JP2012506870A publication Critical patent/JP2012506870A/ja
Publication of JP2012506870A5 publication Critical patent/JP2012506870A5/ja
Application granted granted Critical
Publication of JP5711135B2 publication Critical patent/JP5711135B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533397A 2008-10-24 2009-10-24 胃腸疾患を治療するための方法 Expired - Fee Related JP5711135B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US10811208P 2008-10-24 2008-10-24
US10811008P 2008-10-24 2008-10-24
US10816808P 2008-10-24 2008-10-24
US10813708P 2008-10-24 2008-10-24
US10813408P 2008-10-24 2008-10-24
US61/108,168 2008-10-24
US61/108,112 2008-10-24
US61/108,134 2008-10-24
US61/108,137 2008-10-24
US61/108,110 2008-10-24
US16210909P 2009-03-20 2009-03-20
US61/162,109 2009-03-20
PCT/US2009/061976 WO2010048599A1 (en) 2008-10-24 2009-10-24 Methods for treating gastrointestinal diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014237346A Division JP5908569B2 (ja) 2008-10-24 2014-11-25 胃腸疾患を治療するための方法

Publications (3)

Publication Number Publication Date
JP2012506870A JP2012506870A (ja) 2012-03-22
JP2012506870A5 true JP2012506870A5 (en:Method) 2012-12-06
JP5711135B2 JP5711135B2 (ja) 2015-04-30

Family

ID=42119711

Family Applications (10)

Application Number Title Priority Date Filing Date
JP2011533399A Expired - Fee Related JP5602748B2 (ja) 2008-10-24 2009-10-24 トリアゾール含有マクロライドを用いた生体防御
JP2011533397A Expired - Fee Related JP5711135B2 (ja) 2008-10-24 2009-10-24 胃腸疾患を治療するための方法
JP2011533398A Active JP5715569B2 (ja) 2008-10-24 2009-10-24 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2014167991A Expired - Fee Related JP6002185B2 (ja) 2008-10-24 2014-08-20 トリアゾール含有マクロライドを用いた生体防御
JP2014237428A Active JP5922210B2 (ja) 2008-10-24 2014-11-25 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2014237346A Active JP5908569B2 (ja) 2008-10-24 2014-11-25 胃腸疾患を治療するための方法
JP2016080557A Active JP6309995B2 (ja) 2008-10-24 2016-04-13 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2018047869A Pending JP2018115177A (ja) 2008-10-24 2018-03-15 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2019189322A Pending JP2020023544A (ja) 2008-10-24 2019-10-16 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2021146793A Active JP7171860B2 (ja) 2008-10-24 2021-09-09 トリアゾール含有マクロライドを用いた耐性疾患の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011533399A Expired - Fee Related JP5602748B2 (ja) 2008-10-24 2009-10-24 トリアゾール含有マクロライドを用いた生体防御

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2011533398A Active JP5715569B2 (ja) 2008-10-24 2009-10-24 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2014167991A Expired - Fee Related JP6002185B2 (ja) 2008-10-24 2014-08-20 トリアゾール含有マクロライドを用いた生体防御
JP2014237428A Active JP5922210B2 (ja) 2008-10-24 2014-11-25 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2014237346A Active JP5908569B2 (ja) 2008-10-24 2014-11-25 胃腸疾患を治療するための方法
JP2016080557A Active JP6309995B2 (ja) 2008-10-24 2016-04-13 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2018047869A Pending JP2018115177A (ja) 2008-10-24 2018-03-15 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2019189322A Pending JP2020023544A (ja) 2008-10-24 2019-10-16 トリアゾール含有マクロライドを用いた耐性疾患の治療方法
JP2021146793A Active JP7171860B2 (ja) 2008-10-24 2021-09-09 トリアゾール含有マクロライドを用いた耐性疾患の治療方法

Country Status (11)

Country Link
US (7) US9072759B2 (en:Method)
EP (4) EP2358379B1 (en:Method)
JP (10) JP5602748B2 (en:Method)
CN (4) CN102245195B (en:Method)
AU (4) AU2009308181B2 (en:Method)
DK (1) DK2358379T3 (en:Method)
ES (3) ES2565083T3 (en:Method)
HK (1) HK1252140A1 (en:Method)
HR (1) HRP20160222T1 (en:Method)
SI (1) SI2358379T1 (en:Method)
WO (3) WO2010048601A1 (en:Method)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2801100A1 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Macrolides and processes for their preparation
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
CN102245195B (zh) 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
CN102724874B (zh) 2009-09-10 2018-06-01 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
CN108570083A (zh) * 2010-03-22 2018-09-25 森普拉制药公司 大环内脂的结晶形式及其用途
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
CA2905975A1 (en) * 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
JP6675973B2 (ja) 2013-03-15 2020-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗菌薬を調製するための集束的な方法
MX377459B (es) 2013-04-04 2025-03-10 Harvard College Macrolidos y metodos para su preparacion y uso.
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
US10633407B2 (en) 2014-10-08 2020-04-28 President And Fellows Of Harvard College 14-membered ketolides and methods of their preparation and use
HK1250371A1 (zh) * 2015-03-25 2018-12-14 President And Fellows Of Harvard College 具有修饰的脱氧糖胺糖的大环内酯及其用途
CN106554992A (zh) * 2015-09-28 2017-04-05 中国疾病预防控制中心传染病预防控制所 检测耐红霉素弯曲菌的试剂盒
EP3582615A1 (en) * 2017-02-17 2019-12-25 Cempra Pharmaceuticals, Inc. Triazole-containing macrolides and ophthalmic uses therefor
US10706191B2 (en) * 2017-08-31 2020-07-07 Google Llc Systems and methods for generating a geo-level hierarchical Bayesian model
US11145299B2 (en) 2018-04-19 2021-10-12 X Development Llc Managing voice interface devices

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1354753A (en) 1919-02-11 1920-10-05 E M Lannes Portable building
US2180006A (en) 1936-09-09 1939-11-14 Eastman Kodak Co Process for the separation and refining of amines
GB891817A (en) 1959-04-07 1962-03-21 Upjohn Co Improvements in or relating to injectable tetracyclic preparations
US3843787A (en) 1969-01-15 1974-10-22 Pierrel Spa Water soluble derivative of erythromycin
US3668282A (en) 1970-05-08 1972-06-06 Stauffer Chemical Co Stabilized mixture employing n-(beta-0,0-dialkyldithiophosphoryl) aryl sulfonamides
SE458505B (sv) 1979-07-10 1989-04-10 Lepetit Spa Anvaendningen av rifamycin sv och salter daerav foer framstaellning av en beredning foer behandling av reumatoid artrit samt vissa av salterna och deras framstaellning
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS59175414A (ja) 1983-03-23 1984-10-04 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
DE3860503D1 (de) 1987-09-03 1990-10-04 Pliva Pharm & Chem Works 10-dihydro-10-deoxo-11-azaerythronolid-a-verbindungen,verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln und in deren herstellung.
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
IL114589A (en) 1990-11-21 1999-12-22 Roussel Uclaf Intermediates for the preparation of erythromycin derivatives
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
CA2224275A1 (en) * 1995-06-28 1997-01-16 Tokuyama Corporation Ketonitrile derivatives, and antibacterial agents and drugs containing the same
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
US5742049A (en) * 1995-12-21 1998-04-21 Bruker-Franzen Analytik Gmbh Method of improving mass resolution in time-of-flight mass spectrometry
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
ATE299508T1 (de) 1996-09-04 2005-07-15 Abbott Lab 6-o-substituierte ketoliden mit antibakteriellen wirkung
BR9714394A (pt) 1996-12-13 2000-05-16 Lilly Co Eli Inibidores da atividade enzimática de psa
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
HN1998000074A (es) 1997-06-11 1999-01-08 Pfizer Prod Inc Derivados de macrolidos c-4 sustituidos
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
ID24529A (id) 1997-06-11 2000-07-20 Pfizer Prod Inc Turunan-turunan 9-oksima eritromisin
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
JP3714970B2 (ja) * 1998-03-26 2005-11-09 アステラス製薬株式会社 徐放性製剤
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
ES2273964T3 (es) 1998-12-10 2007-05-16 Pfizer Products Inc. Antibioticos de carbamato y carbazato cetolida.
ATE256694T1 (de) 1999-01-27 2004-01-15 Pfizer Prod Inc Ketolid-antibiotika
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
FR2789392B1 (fr) 1999-02-04 2001-10-05 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
AR023264A1 (es) 1999-04-08 2002-09-04 Hokuriku Pharmaceutical Derivados de eritromicina
JP2000351794A (ja) 1999-04-08 2000-12-19 Hokuriku Seiyaku Co Ltd エリスロマイシン誘導体
MXPA01010521A (es) 1999-04-16 2003-08-19 Johnson & Johnson Antibacteriales de cetolidos.
EP1171446B1 (en) 1999-04-16 2006-09-20 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
AU3337900A (en) 1999-08-09 2001-03-05 Eric Au An apparatus for treating wastewater
US6096922A (en) 1999-11-01 2000-08-01 Air Products And Chemicals, Inc. Process for the synthesis of dialkyl, diaryl, and arylalkyl aminosulfur trifluorides
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
AU771825B2 (en) 2000-03-15 2004-04-01 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form II crystals
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US20020115621A1 (en) * 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
EP2186508A3 (en) 2001-05-18 2010-08-25 Novartis AG Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
AU2002316550A1 (en) 2001-07-03 2003-01-21 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
AR038576A1 (es) 2002-02-22 2005-01-19 Pharmacia Corp Formulaciones de drogas antibioticas oftalmicas que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio
DK2226316T3 (en) 2002-05-30 2016-04-11 Scripps Research Inst Copper catalyzed ligation of azides and acetylenes
WO2004012653A2 (en) 2002-06-17 2004-02-12 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof
PL374731A1 (en) 2002-07-08 2005-10-31 Pliva-Istrazivacki Institut D.O.O. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
CA2801100A1 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Macrolides and processes for their preparation
US7332476B2 (en) 2003-04-25 2008-02-19 Novartis Ag Pyridyl substituted ketolide antibiotics
US7163924B2 (en) 2003-04-25 2007-01-16 Chiron Corporation Ketolide derivatives
SI1628989T1 (sl) 2003-05-13 2007-06-30 Glaxo Group Ltd Nove cikliäśne spojine s 14 in 15 obroäśnimi äśleni
US20050014706A1 (en) 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
GB0402578D0 (en) 2004-02-05 2004-03-10 Cambridge Theranostics Ltd Methods of treatment of atherosclerosis
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
WO2005105821A2 (en) 2004-04-28 2005-11-10 Alembic Limited Process for the preparation of telithromycin
CA2566085A1 (en) 2004-05-06 2005-11-17 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O Ester linked macrolides useful for the treatment of microbial infections
RU2397987C2 (ru) 2004-07-28 2010-08-27 Рэнбакси Лабораториз Лимитед Кетолидные производные в качестве антибактериальных агентов
GB0424958D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
GB0424959D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
ATE477805T1 (de) 2005-01-14 2010-09-15 Glaxosmithkline Zagreb 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
ES2371931T3 (es) 2005-01-14 2012-01-11 Glaxo Group Limited Compuestos macrólidos que contienen biotina y grupo con foto-afinidad para la identificación de la diana del macrólido.
ES2326002T3 (es) 2005-01-14 2009-09-28 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9a-carbamoil y tiocarbamoil azalidos con actividad antipaludica.
WO2006102283A2 (en) 2005-03-22 2006-09-28 Azevan Pharmaceuticals, Inc. Beta-lactamylalkanoic acids for treating premenstrual disorders
EP1904041A2 (en) 2005-07-07 2008-04-02 Elan Pharma International Limited Nanoparticulate clarithromycin formulations
EP1910346B1 (en) 2005-07-19 2019-02-27 Azevan Pharmaceuticals, Inc. Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonist
EP1945654B1 (en) 2005-10-31 2015-08-19 Leo Pharma A/S Preparation of an antibiotic crystalline fusidic acid
GB0522715D0 (en) 2005-11-08 2005-12-14 Helperby Therapeutics Ltd New use
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
EP1957508A2 (en) * 2005-11-23 2008-08-20 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
EP1954294A2 (en) 2005-11-23 2008-08-13 Ranbaxy Laboratories Limited Use of macrolide derivatives for treating acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101045063B (zh) 2006-03-28 2011-01-26 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
RU2455308C2 (ru) 2006-05-01 2012-07-10 Тайсо Фармасьютикал Ко., Лтд. Макролидные производные
JP2009539866A (ja) 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
DE102006036199B4 (de) * 2006-08-03 2016-01-07 Deere & Company Förderzusammenbau und Presse
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US20090209547A1 (en) * 2008-02-15 2009-08-20 In Jong Kim C-8 halogenated macrolides
CN102245195B (zh) 2008-10-24 2016-01-13 森普拉制药公司 使用含三唑的大环内酯的生物防御
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
CA2767614C (en) 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CN102724874B (zh) 2009-09-10 2018-06-01 森普拉制药公司 治疗疟疾、结核病和mac疾病的方法
US20110119604A1 (en) 2009-11-19 2011-05-19 Clevest Solutions Inc. System and method for a configurable and extensible allocation and scheduling tool
EP2544537B1 (en) 2010-03-10 2017-05-10 Cempra Pharmaceuticals, Inc. Parenteral formulations of macrolide antibiotics
CN108570083A (zh) 2010-03-22 2018-09-25 森普拉制药公司 大环内脂的结晶形式及其用途
CN102917708B (zh) 2010-05-20 2015-11-25 森普拉制药公司 制备大环内酯和酮内酯及其中间体的方法
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US9260473B2 (en) 2010-07-19 2016-02-16 Virginia Commonwealth University Bivalent multifunctional ligands targeting Aβ oligomers as treatment for Alzheimer's disease
US20130164351A1 (en) 2010-08-30 2013-06-27 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
WO2012042534A2 (en) 2010-09-28 2012-04-05 Glenmark Generics Limited Processes for the preparation of r-sitagliptin and intermediates thereof
WO2012162439A2 (en) 2011-05-23 2012-11-29 Cem-102 Pharmaceuticals, Inc. Compositions comprising fusidic acid and packages therefor
PL2748165T3 (pl) 2011-08-27 2017-05-31 Wockhardt Limited Pochodne 1,6-diazabicyklo[3,2,1]oktan-7-onu i ich zastosowanie w leczeniu zakażeń bakteryjnych
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2013059610A1 (en) 2011-10-20 2013-04-25 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
KR20140139083A (ko) 2012-03-27 2014-12-04 셈프라 파마슈티컬스, 인크. 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
CA2905975A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
JP6675973B2 (ja) 2013-03-15 2020-04-08 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗菌薬を調製するための集束的な方法
MX377459B (es) 2013-04-04 2025-03-10 Harvard College Macrolidos y metodos para su preparacion y uso.
EP3105234A4 (en) 2014-02-14 2017-11-08 Cempra Pharmaceuticals, Inc. Compositions and methods for treating diabetes and liver diseases
WO2015181723A1 (en) 2014-05-27 2015-12-03 Dipharma Francis S.R.L. Azidoalkylamine salts and their use as intermediates
CA2957034A1 (en) 2014-08-05 2016-02-11 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
CN107405355A (zh) 2015-03-06 2017-11-28 森普拉制药公司 用于制备氟酮内酯的方法

Similar Documents

Publication Publication Date Title
JP2012506870A5 (en:Method)
JP2012506872A5 (en:Method)
JP2012506871A5 (en:Method)
JP2021063088A5 (en:Method)
JP2015078203A5 (en:Method)
JP2009502743A5 (en:Method)
JP2011528713A5 (en:Method)
JP2015078220A5 (en:Method)
JP2009535352A5 (en:Method)
JP2016515561A5 (en:Method)
JP2006523216A5 (en:Method)
JP2012510461A5 (en:Method)
JP2010540556A5 (en:Method)
JP2015061858A5 (en:Method)
JP2011530534A5 (en:Method)
MX2010002278A (es) Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
JP2017531619A5 (en:Method)
JP2016515628A5 (en:Method)
JP2014530818A5 (en:Method)
RU2018114480A (ru) Соли и твердые формы монобактамного антибиотика
JP2019507764A5 (en:Method)
JP2017505785A5 (en:Method)
JP2016502981A5 (en:Method)
JP2016531885A5 (en:Method)
JP2015510916A5 (en:Method)